#Obesity medicine
Chronic weight management as a clinical specialty.
Semaglutide and OA: beyond weight loss
A 2026 preclinical study shows semaglutide reduces cartilage damage and joint pain without weight change, via GLP-1R activation of autophagy in chondrocytes.
Tirzepatide vs semaglutide: real-world data
A 511-patient real-world study in Mayo Clinic Proceedings found tirzepatide produced 16.6% vs 13.4% mean weight loss for semaglutide over 12 months.
CagriSema pen usability: the study results
A 150-person study tested whether adults with overweight or diabetes could use the CagriSema dual-chamber autoinjector correctly after 3 minutes of training.
GLP-1 drugs in Medicaid: the coverage gap
Most US Medicaid programs restrict or exclude GLP-1 obesity drugs. Here is what the research says about who gets access and why coverage varies by state.
Semaglutide and diabetes recovery stories
A 2026 medical humanities paper asks what happens to patient recovery narratives when semaglutide does much of the biological work.
Semaglutide and weight in schizophrenia
A 24-week trial found semaglutide reduced body weight by 9.8% in people with schizophrenia on clozapine or olanzapine, with partial regain after stopping.
GLP-1 drugs and mental health: a 2026 study
A June 2026 cohort study found lower rates of anxiety and depression in adults on tirzepatide or semaglutide vs other weight-loss drugs, and what that means.
Tirzepatide and steatotic liver disease
A 2026 real-world study finds tirzepatide cut major liver complications and mortality in adults with steatotic liver disease and cardiometabolic dysfunction.
GLP-1/GIPR/FGF21 peptibody in DIO mice
A preclinical peptibody hitting GLP-1, GIPR, and FGF21 reduced body weight and improved metabolic markers in obese mice. Human translation is unknown.
Weight-loss drugs and hypertension
A Cochrane review of eight trials finds insufficient evidence that weight-loss drugs cut mortality or cardiovascular events in hypertensive patients.
GLP-1 drugs improve ratio but cut muscle
A 2026 meta-analysis of 7 RCTs finds GLP-1 receptor agonists raise the lean-to-fat ratio while causing a 1.74 kg average absolute lean mass loss.
GLP-1 drugs and lung safety: what we know
A 2026 systematic review examines pulmonary adverse events with GLP-1 receptor agonists, from mild upper-airway infections to perioperative aspiration risk.